- Bispecific antibodies best experts
- 2 therapeutic antibodies on the market
- 300+ mAbs successfully developed
BISPECIFIC ANTIBODY DEVELOPMENT SERVICES
ProteoGenix gives you access to the best expertise in bispecific antibody development: 2 therapeutic antibodies on the market, 300+ monoclonal antibodies successfully developed, scientists having more than 25 years of experience in therapeutic antibody development. Choose the best knowledge in bispecific antibody format generation to construct your blockbuster.
Bispecific antibody design
Why choose ProteoGenix for your bispecific antibody development projects?
widest range of bispecific antibody format engineering on the market.
2 therapeutic antibodies on the market, 300 monoclonal successfully developed, 15 years of experience in monoclonal antibody
Short turnaround time
8 weeks from antibody sequence to mg of bispecific antibody is our fastest project record!
a straight line from your idea to bioproduction.
IP free proprietary cell line
our unrivalled proprietary cell line developed for high-yield antibody expression.
Protein production expert
1500+ proteins expressed in 5 different systems.
Our bispecific antibody development process
ProteoGenix offers the best-in-class one-stop solution for your bispecific antibody development project. Get access to:
The expertise of renowned scientists having more than 25 years of experience in the development of therapeutic monoclonal antibodies,
Experts which successfully developed more than 300 monoclonal antibodies in 15 years including 2 therapeutic monoclonal antibodies currently on the market.
Send us your requirements, our team:
Defines the most accurate format for your application and for further pharmaceutical production (“developability”),
Adapts the available format to your antibody sequences,
Expresses and purify complex bispecific antibody formats,
Optimizes and characterizes the best bispecific antibody formats.
Our complete bispecific antibody development service includes:
Your optimized and purified bispecific antibody,
A complete report with description of the experimental steps, results, discussion and conclusion,
Optional : an optimized bispecific antibody production process directly transferrable to your CMO (parameters optimized includes: HC/LC ratio, expression system, linkers and many others depending on the project),
All the property of the work done by ProteoGenix is transferred to the client.
Choosing ProteoGenix also means getting access to our best-in-class proprietary cell line XtenCHOTM. Why best-in-class? Because it is the only cell line which already overperformed ExpiCHO, the reference on the market, for the transient expression of therapeutic antibodies such as Pembrolizumab and many others (yields of up to 800 mg/L).
Unleash the potential of your project by choosing ProteoGenix as your privileged partner!
Bispecific antibody engineering:
get access to the largest variety of structures
Bispecific antibodies were initially produced using the quadroma method (hybrid hybridoma). This technique allows to produce antibodies in a single host cell but leads to a mixture of tailored compound, nonfunctional and homodimer compounds. Thus, producing bispecific antibodies (BsAb) with sufficiently high yields to reach bioproduction was a true challenge due to heavy chain and light chain mispairing.
The heavy chain mispairing challenge was overcome in the 90s thanks to the engineering of the CH3 domains which controls the heavy chain dimerization. Several strategies were employed to force antibody heavy chain heterodimerization over homodimerization such as the well-known “knob-into-hole” approach or electrostatic steering mutations.
To avoid light chain mispairing, several approaches were also developed in the last decade. One of these consists in completely circumventing the issue by using identical light chains. Other examples of strategy imply separate expression of monoclonal antibodies before assembly in a single-host cell (Duobody, Genmab) or rearrangement of the heterodimerization interface by swapping between a heavy and a light chain domain (CrossMAb, Roche).
The capacity to assemble a large variety of building blocks opens the door to an infinite number of bispecific antibody formats. Controlling the various engineering technics means getting access to the capacity to perfectly modulate the pharmacological properties of the desired compound and thus to develop your blockbuster. For this reason, choosing a company with more than 15 years of experience in antibody engineering like ProteoGenix ensures the success of your project. Our scientific experts already overcome the most difficult engineering challenges, that’s why it’s time to place yours in safe hands!
Choosing a bispecific antibody format: a crucial step on the road to success
The recombinant bispecific antibody production technology paved the way to the generation of various bispecific antibody formats which can be classified according to their format and composition. Several differences distinguish bispecific antibodies:
The presence or absence of a Fc region,
The number of binding sites.
The intensity of research activity and diversity of the bispecific antibody formats created demonstrates that a unique format cannot fit all applications. Here are some examples of formats currently in preclinical or Phase I clinical trial demonstrating the strong potential of this class of compounds as biotherapeutics and the importance of choosing the right format: CrossMAb, DuoBody, κλ-body, SEEDbody, nanobody, BiTE, DART…
Thus, it becomes particularly important to select a partner that can guide you through the difficult format selection process. With several experts having long-standing experience in the development of therapeutic monoclonal antibodies, ProteoGenix proposes you the very best of the scientific knowledge related to the field.
Bispecific antibody fragments
Bispecific IgG and IgG-like
Dock and Lock
Bispecific antibody conjugates
Bispecific antibody fragments
Bispecific IgG and IgG-like
Dock and Lock
Bispecific antibody conjugates
CROSSMAB: BISPECIFIC IGG-LIKE
CrossMAb is a bispecific IgG format developed by Roche to overcome the LC/HC mispairing. This technology is based on the exchanging of the light chain and heavy chain domain within a unique Fab arm to induce specific interaction while keeping the original antigen binding affinity.
CrossMAb can be combined with the KiH approach to control both HC/HC and LC/HC pairing.
As a bispecific IgG, CrossMAb combines the advantages of IgG (long pharmacokinetic in vivo half-life, effector functions) and bispecific antibodies.
DUOBODY: BISPECIFIC IGG-LIKE
The DuoBody platform is a technology invented by Genmab based on a controlled Fab arm exchange. This technique is based on the separate expression of two IgG1, each of them containing a single matched mutation in the CH3 domain. The obtained antibodies are further mixed and separated into half molecules under reducing conditions. Single point mutations introduced in each Fab arm coupled with oxidizing conditions control the reassembly of half molecules leading to yields of bispecific IgG of up to 95%.
Like CrossMAb, Duobody combines the advantages of IgG and bispecific antibodies.
DART: BISPECIFIC ANTIBODY FRAGMENT
The DART format can be classified as a bispecific antibody fragment. DART is a diabody composed of the variable domains of two different antibodies. In this format, the variable heavy domain of the first antibody is connected via a short peptide linker to the variable light domain of the second antibody and vice versa leading to two scFv. Generation of DART is obtained by further stabilization via disulfide bond.
Like most small formats, DART are characterized by a high potency but a short serum half-life but can be further engineered to overcome this limitation, for example by fusion to a Fc region.
NANOBODY: BISPECIFIC ANTIBODY FRAGMENT
Nanobodies correspond to single domain antibody fragments which can be obtained from various species, such as llama or alpaca. Bispecificity can be obtained by connecting two nanobodies via short linkers.
The high-potential of nanobodies comes from their small size which allows access to antigen access that would not be sterically accessible to other antibodies.
Like DART, bispecific nanobodies are characterized by a high potency but a short half-life which can be overcome by connection by fusion to a protein such as human serum albumin (HSA).
DVD-IG: APPENDED IGG
DVD-Ig (dual variable domain-Ig) is part of the appended IgG family and was developed by Abbott. Appended IgG correspond to monoclonal IgG that have been further engineered to introduce bispecifity by addition of antigen binding sites at the N- or C- termini of either light chains or heavy chains. DVD-Ig are obtained by appending VL and VH domain of an antibody to an IgG and results in a bispecific and bivalent antibody for each antigen.
κλ-BODY: BISPECIFIC IGG
κλ-body is a fully-human bispecific IgG recently developed by Novimmune to solve the LC/HC mispairing issue. This format is characterized by a common heavy chain coupled with two different light chains κ and λ governing the antigen-binding specificity. The process developed by Novimmune is based on the selection of light chains via phage display.
SEEDBODY: BISPECIFIC IGG-LIKE
SEEDbody is a bispecific antibody format developed by Merck Serono which overcomes the HC/HC mispairing issue. SEED method is based on the alternation of human IgG and IgA sequences in the CH3 domain in order to favor the heterodimerization.
SEEDbody is a bispecific IgG and thus combines the advantages of IgG and bispecific antibodies.
TRIOMAB: BISPECIFIC IGG-LIKE
Triomab is a format developed by Trion Pharma and was the first bispecific antibody approved on the market for therapeutic application. Triomab is based on the quadroma production technique which is generally associated with HC/HC and LC/HC mispairing problems. Trion Pharma overcame both of these issues by generating a mouse/rat hybrid hybridoma.
LC/HC mispairing was solved by combining mouse IgG2a and rat IgG2b.
HC/HC mispairing was solved during the purification steps as mouse IgG2a have strong affinity for protein A on the contrary to rat IgG2b.
Use of bispecific antibodies as biotherapeutics
Antibodies are one of the fastest growing class of therapeutics mainly because they demonstrated their ability to improve the treatments of several complex diseases such as cancer or inflammatory disorders.
This success has fueled strong interest in the development and engineering of new antibody drugs including bispecific antibodies. The major advantage of bispecific antibodies over monospecific antibodies is their capacity to bind two different antigens or two epitopes of the same antigen. This specific property paves the way to a new generation of high potential biotherapeutics.
Up to date, three bispecific antibodies were approved for clinical use:
Catumaxomab (REMOVAB®) is a T-cell recruiter developed by Trion Pharma which binds EpCAM and CD3. Catumaxomab is a nonhuman bispecific IgG-like rat/mouse antibody produced using the quadroma technology which was indicated as a treatment for malignant ascites (withdrawn in 2014).
Blinatumomab (BLINCYTO®) is a BiTE developed by Amgen and Micromet. It is a T-cell recruiter which targets CD3 positive T-cell and CD19 positive B-cells. Blinatumomab is indicated for the treatment of acute lymphoblastic leukemia.
Emicizumab (HEMLIBRA®) is a therapeutic antibody developed by Roche and Chugai. This bispecific antibody induces the dimerization of its two targets (Factor IX and Factor X) in order to reactivate the latter. Emicizumab is indicated for the treatment of hemophilia A.
The most common application of bispecific antibodies relies on the retargeting of effector cells to tumor cells for cancer therapy. BiTE (bispecific T-cell Engager) is an example of format (developed by Micromet) based on this application. BiTE can be considered as a scFv tandem which targets a T-cell specific molecule on the one hand and a tumor specific antigen on the other hand to improve patient’s immune response.
Bispecific antibodies can also overcome other limitations of monospecific antibodies. An example is their inability to cross the blood-brain barrier as the low permeability of the BBB hinders the development of antibodies which target an antigen in the CNS. A strategy currently discussed to cross the BBB consists in engineering bispecific antibodies that recognize a BBB receptor (to induce transcystosis) and the target within the CNS.
Due to their high diversity, bispecific antibodies can present many other therapeutic applications such as:
Inhibiting two pathways at the same time,
Enhancing antigen binding affinity,
Increasing target specifity,
And even more…
Bispecific antibody development services that will reach your expectations and even more!
At ProteoGenix, we know that bispecific antibody engineering and design is only one step of the road to success. For this reason, we attach particular importance to guide you along the development of your bispecific antibody until bioproduction. ProteoGenix has an extensive experience in the development of stable cell lines reaching high production yields and no undesired side products. With ProteoGenix, you can be sure that our scientists will be fully committed to converting your ideas into a blockbuster.